Pfizer's Anti-Viral Drug In The United States. What It Is And How It Works?
The History of Pfizer.
Drugs and prescription medicines are an integral part of a person's everyday life. From going to the doctor for the flu or cold, to giving a pill to relieve a headache or a fever, they are often called upon to save a patient's life.
This has given rise to major pharmaceutical companies that manufacture these drugs to treat patients with different ailments. Pfizer, Inc., which is the first pharmaceutical company to manufacture the antiviral drug in the United States, is one such giant pharmaceutical company.
The history of Pfizer in the United States, which was started in 1886, is said to be a major contributor in the research and development of anti-viral drugs.
The Drug.
Pfizer is developing PF-06478242, an anti-viral treatment for avian influenza type A virus infection.
In a press release dated Sept. 19, 2017, the company made reference to a single late-stage study demonstrating proof-of-concept for efficacy in an elderly patient population, specifically influenza A subtype H7N9. In addition, a Phase 2/3 study of the treatment was also reported, with an investigational 2nd generation NS5A therapeutic vaccine (a novel, recombinant anti-influenza neuraminidase inhibitor) administered in combination with TIVO-3.
The treatment is being developed through the Company's Vaccines and Anti-Influenza Therapeutics Research (VATR) program. The program "is directed to developing a novel, fusion protein immuno-oncology agent.
What is it?
Pfizer's patent-protected drug would be administered to reduce the duration of the flu-like symptoms experienced during the first 21 days of treatment and if these symptoms persist, the treatment would be provided for a longer period. As for how exactly the treatment will be administered, it is expected that it will be a nasal spray which is a common way of delivering such treatments in the United States. The treatment is expected to be provided in two doses of two to four sprays with every day of the week.
How will it benefit my healthcare provider?
• Preliminary studies conducted by the drug company have indicated that the drug is effective and safe for use.
• It is a needleless, self-administered treatment, and the risk of infection is reduced as much as possible.
How does it work?
Pfizer is expected to conduct several clinical trials with Velcade before making it available to people in the United States. The drug is designed to help people with the most common form of multiple myeloma survive an average of 3 months longer.
"It's important to remember that many multiple myeloma patients suffer long-term side effects of their disease," said Charles Mulligan, M.D., executive vice president and general manager of Oncology at Pfizer. "And many are in need of treatment options that can bring them closer to a normal, healthy life."
SUMMARY
Multiple myeloma is a type of blood cancer that starts in plasma cells in the bone marrow. The plasma cells normally make antibodies that prevent the disease from spreading and destroying healthy cells in the body.
Making drugs accessible to people in the United States.
Making the drugs available to people immediately upon the approval
Accessing new patients via potential partnerships
Key to the achievement of the above is one of the first products that will be available under the affordable healthcare program. Per the condition, the drug will be provided at an affordable rate to both the government and patients. The total cost for patients will be as low as $150, which will be paid in four installments and the drug will be delivered directly to their respective home. To further promote its promotion, the government will be financing the cost of the drug for both the government and patients.
Under the new plan, patients will not be forced to pay the full retail price of the drug.
Conclusion.
In simple terms, Oseltamivir is designed to be an antiviral treatment to combat the virus that is responsible for the flu virus. While the science behind this medication may not sound too exciting, it has the potential to lead to significant revenue for the company. The overall payer profile for the medication is anticipated to have a favorable trajectory as it has demonstrated a strong efficacy and safety profile. What this means is that not only will the drug receive a strong approval from the FDA, but it will also garner a favorable trajectory once it's launched. With this, we're looking at a significant value creation opportunity.
Overall, the drug is anticipated to be successful and transform the company.
0 Comments